Accuray (ARAY)
Market Price (7/21/2026): $0.249 | Market Cap: $31.0 MilSector: Health Care | Industry: Life Sciences Tools & Services
Accuray (ARAY)
Market Price (7/21/2026): $0.249Market Cap: $31.0 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -33% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, Precision Medicine, and Digital Health & Telemedicine. Themes include Oncology Treatments, Show more. | Weak multi-year price returns2Y Excs Rtn is -120%, 3Y Excs Rtn is -160% | Penny stockMkt Price is 0.3 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -15 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -3.5% Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 464% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -7.9%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.6%, Rev Chg QQuarterly Revenue Change % is -7.4% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -4.5%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -7.8% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -153% Key risksARAY key risks include [1] persistent financial distress and unprofitability, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -33% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, Precision Medicine, and Digital Health & Telemedicine. Themes include Oncology Treatments, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -120%, 3Y Excs Rtn is -160% |
| Penny stockMkt Price is 0.3 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -15 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -3.5% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 464% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -7.9%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.6%, Rev Chg QQuarterly Revenue Change % is -7.4% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -4.5%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -7.8% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -153% |
| Key risksARAY key risks include [1] persistent financial distress and unprofitability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Accuray (ARAY) stock has lost about 35% since 3/31/2026 because of the following key factors:
1. Accuray reported weaker-than-expected financial results for fiscal Q3 2026.
The company announced its fiscal Q3 2026 earnings, which ended March 31, 2026, on May 6, 2026. Accuray posted an earnings per share (EPS) of -$0.09, missing the forecasted -$0.02, and reported revenue of $104.8 million, falling short of the anticipated $111.9 million. This represented a 7% year-over-year decline in total net revenue. Product revenue specifically decreased by 13% to $49.7 million, and service revenue saw a 1% decline to $55.1 million in fiscal Q3 2026. Furthermore, gross product orders were $48.5 million, a decrease from $71.2 million in the prior fiscal year third quarter, and the order backlog as of March 31, 2026, was $356.2 million, approximately 21% lower than the end of the prior fiscal year third quarter.
2. The company withdrew its fiscal year 2026 financial guidance due to geopolitical uncertainty.
Following the release of its fiscal Q3 2026 results on May 6, 2026, Accuray withdrew its financial guidance for fiscal year 2026. The company cited ongoing geopolitical uncertainty in the Middle East as the primary reason, noting that these conditions were materially impacting product shipments and service revenue, leading to delays in installations in several markets within the region.
Show more
Accuray (ARAY) stock has lost about 35% since 3/31/2026 because of the following key factors:
1. Accuray reported weaker-than-expected financial results for fiscal Q3 2026.
The company announced its fiscal Q3 2026 earnings, which ended March 31, 2026, on May 6, 2026. Accuray posted an earnings per share (EPS) of -$0.09, missing the forecasted -$0.02, and reported revenue of $104.8 million, falling short of the anticipated $111.9 million. This represented a 7% year-over-year decline in total net revenue. Product revenue specifically decreased by 13% to $49.7 million, and service revenue saw a 1% decline to $55.1 million in fiscal Q3 2026. Furthermore, gross product orders were $48.5 million, a decrease from $71.2 million in the prior fiscal year third quarter, and the order backlog as of March 31, 2026, was $356.2 million, approximately 21% lower than the end of the prior fiscal year third quarter.
2. The company withdrew its fiscal year 2026 financial guidance due to geopolitical uncertainty.
Following the release of its fiscal Q3 2026 results on May 6, 2026, Accuray withdrew its financial guidance for fiscal year 2026. The company cited ongoing geopolitical uncertainty in the Middle East as the primary reason, noting that these conditions were materially impacting product shipments and service revenue, leading to delays in installations in several markets within the region.
3. Multiple analyst downgrades and significant price target reductions followed the negative news.
In response to Accuray's fiscal Q3 2026 earnings miss and the withdrawal of its guidance, several analysts downgraded the stock. On May 12, 2026, Jefferies downgraded Accuray (ARAY) to Hold from Buy and drastically cut its price target by approximately 89%, from $3.05 to $0.35, noting that the issues appeared to be more structural in nature. Similarly, BTIG downgraded Accuray from Buy to Neutral, citing ongoing revenue challenges and the withdrawal of financial guidance. The consensus rating for Accuray subsequently shifted to "Reduce" among Wall Street analysts.
Show less
Stock Movement Drivers
Fundamental Drivers
The -34.3% change in ARAY stock from 3/31/2026 to 7/21/2026 was primarily driven by a -31.2% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 7212026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.39 | 0.26 | -34.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 437 | 429 | -1.9% |
| P/S Multiple | 0.1 | 0.1 | -31.2% |
| Shares Outstanding (Mil) | 121 | 124 | -2.7% |
| Cumulative Contribution | -34.3% |
Market Drivers
3/31/2026 to 7/21/2026| Return | Correlation | |
|---|---|---|
| ARAY | -35.6% | |
| Market (SPY) | 15.1% | 25.0% |
| Sector (XLV) | 9.3% | -13.1% |
Fundamental Drivers
The -69.1% change in ARAY stock from 12/31/2025 to 7/21/2026 was primarily driven by a -66.0% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 7212026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.82 | 0.26 | -69.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 451 | 429 | -5.0% |
| P/S Multiple | 0.2 | 0.1 | -66.0% |
| Shares Outstanding (Mil) | 119 | 124 | -4.3% |
| Cumulative Contribution | -69.1% |
Market Drivers
12/31/2025 to 7/21/2026| Return | Correlation | |
|---|---|---|
| ARAY | -69.7% | |
| Market (SPY) | 10.0% | 29.9% |
| Sector (XLV) | 3.9% | 0.6% |
Fundamental Drivers
The -81.4% change in ARAY stock from 6/30/2025 to 7/21/2026 was primarily driven by a -75.6% change in the company's P/S Multiple.| (LTM values as of) | 6302025 | 7212026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.37 | 0.26 | -81.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 465 | 429 | -7.9% |
| P/S Multiple | 0.3 | 0.1 | -75.6% |
| Shares Outstanding (Mil) | 103 | 124 | -17.3% |
| Cumulative Contribution | -81.4% |
Market Drivers
6/30/2025 to 7/21/2026| Return | Correlation | |
|---|---|---|
| ARAY | -81.7% | |
| Market (SPY) | 22.1% | 31.8% |
| Sector (XLV) | 20.4% | 6.9% |
Fundamental Drivers
The -93.4% change in ARAY stock from 6/30/2023 to 7/21/2026 was primarily driven by a -91.2% change in the company's P/S Multiple.| (LTM values as of) | 6302023 | 7212026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.87 | 0.26 | -93.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 439 | 429 | -2.5% |
| P/S Multiple | 0.8 | 0.1 | -91.2% |
| Shares Outstanding (Mil) | 96 | 124 | -23.2% |
| Cumulative Contribution | -93.4% |
Market Drivers
6/30/2023 to 7/21/2026| Return | Correlation | |
|---|---|---|
| ARAY | -93.5% | |
| Market (SPY) | 74.8% | 33.2% |
| Sector (XLV) | 26.4% | 20.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ARAY Return | 14% | -56% | 35% | -30% | -58% | -70% | -94% |
| Peers Return | 7% | -17% | 30% | 22% | 5% | -21% | 17% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 98% |
Monthly Win Rates [3] | |||||||
| ARAY Win Rate | 33% | 33% | 67% | 42% | 25% | 14% | |
| Peers Win Rate | 43% | 48% | 50% | 62% | 55% | 31% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| ARAY Max Drawdown | -41% | -63% | -43% | -52% | -70% | -73% | |
| Peers Max Drawdown | -32% | -37% | -30% | -25% | -27% | -40% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CATX, ISRG, SYK, MDT, BSX. See ARAY Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/21/2026 (YTD)
How Low Can It Go
| Event | ARAY | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -16.6% | -7.8% |
| % Gain to Breakeven | 19.9% | 8.5% |
| Time to Breakeven | 3 days | 18 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -15.1% | -6.7% |
| % Gain to Breakeven | 17.8% | 7.1% |
| Time to Breakeven | 2 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -60.5% | -33.7% |
| % Gain to Breakeven | 153.3% | 50.9% |
| Time to Breakeven | 232 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -22.8% | -19.2% |
| % Gain to Breakeven | 29.6% | 23.8% |
| Time to Breakeven | 30 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -19.5% | -12.2% |
| % Gain to Breakeven | 24.2% | 13.9% |
| Time to Breakeven | 68 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -57.5% | -17.9% |
| % Gain to Breakeven | 135.5% | 21.8% |
| Time to Breakeven | 793 days | 123 days |
In The Past
Accuray's stock fell -16.6% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 19.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ARAY | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -60.5% | -33.7% |
| % Gain to Breakeven | 153.3% | 50.9% |
| Time to Breakeven | 232 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -22.8% | -19.2% |
| % Gain to Breakeven | 29.6% | 23.8% |
| Time to Breakeven | 30 days | 105 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -57.5% | -17.9% |
| % Gain to Breakeven | 135.5% | 21.8% |
| Time to Breakeven | 793 days | 123 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -36.6% | -8.6% |
| % Gain to Breakeven | 57.7% | 9.5% |
| Time to Breakeven | 68 days | 47 days |
In The Past
Accuray's stock fell -16.6% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 19.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Accuray (ARAY)
Accuray Incorporated (ARAY) is a medical device company specializing in the design, development, manufacturing, and sale of advanced radiosurgery and radiation therapy systems. These sophisticated systems are primarily used for the precise treatment of various types of tumors and cancers throughout the body, offering innovative solutions for oncology departments worldwide.
The company's core product offerings include the CyberKnife System, a robotic platform for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) that targets tumors in areas like the prostate, lung, brain, and liver with high accuracy. Additionally, Accuray provides the TomoTherapy System, which includes the Radixact System, an integrated radiation therapy solution designed to treat a wide spectrum of cancer types. Beyond equipment sales, Accuray also offers essential post-contract services such as installation, training, and ongoing customer support to ensure optimal system performance.
Accuray primarily serves healthcare providers, specifically hospitals and stand-alone cancer treatment facilities. The company operates globally, with a significant presence across the Americas, Europe, the Middle East, India, Africa, Japan, and the broader Asia Pacific region. Sales are conducted through a direct sales force, as well as via sales agents, distributors, and group purchasing organizations to reach its diverse international customer base.
AI Analysis | Feedback
Here are 1-3 brief analogies for Accuray:
- Accuray is like Intuitive Surgical, but for robotic cancer radiation therapy systems instead of general robotic surgery.
- Imagine a highly specialized GE Healthcare or Siemens Healthineers, focusing solely on advanced systems for treating cancer with radiation.
AI Analysis | Feedback
- CyberKnife System: A robotic system used for stereotactic radiosurgery and stereotactic body radiation therapy to treat various types of cancer and tumors.
- TomoTherapy System (including Radixact System): An integrated radiation therapy system designed for the treatment of a wide range of cancer types.
- Professional Services: Includes post-contract customer support, installation, and training for their radiosurgery and radiation therapy systems.
AI Analysis | Feedback
Accuray (ARAY) primarily sells its radiosurgery and radiation therapy systems to the following categories of customers:
- Hospitals
- Stand-alone treatment facilities
AI Analysis | Feedback
AI Analysis | Feedback
Steve La Neve, Chief Executive Officer
Steve La Neve was appointed Chief Executive Officer of Accuray in October 2025, bringing over 40 years of international medical technology experience to the role. Prior to Accuray, he served as President of the Trauma and Joint Reconstruction business unit of Globus Medical Inc. and as CEO of Bone Biologics Corporation. He also held the position of Global President of Becton Dickinson Preanalytical Systems. Earlier in his career, Mr. La Neve was Global Sector President for Medtronic's Spine and Biologics Division and President & CEO of ETEX Corporation, where he successfully led the sale of the business.
Ali Pervaiz, Senior Vice President, Chief Financial Officer
Ali Pervaiz was appointed Senior Vice President and Chief Financial Officer of Accuray in May 2022. He joined Accuray in August 2020 as Vice President, Global Commercial Operations. Mr. Pervaiz has an 18-year career in the medical technology industry, with over 15 years spent at GE Healthcare in senior financial and operating leadership roles. His previous roles at GE Healthcare included Chief Financial Officer for two business units: the US Imaging Equipment and US Life Support Solutions businesses. He began his finance career in GE's Corporate Audit Staff program.
Sandeep Chalke, Senior Vice President, Chief Commercial Officer
Sandeep Chalke serves as Accuray's Senior Vice President, Chief Commercial Officer. In this role, he is responsible for the company's commercial operations.
Leonel Peralta, Senior Vice President, Chief Operations Officer
Leonel Peralta is the Senior Vice President, Chief Operations Officer at Accuray.
Seth Blacksburg M.D., MBA, Senior Vice President, Chief Medical Officer
Seth Blacksburg holds the position of Senior Vice President, Chief Medical Officer at Accuray.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Accuray (ARAY) operates in the radiation oncology market, with its main products being the CyberKnife System and the TomoTherapy System, which includes the Radixact System. The addressable markets for these products are substantial and projected to grow.
CyberKnife System
The global CyberKnife market was estimated at USD 637.4 million in 2024 and is projected to reach USD 1,788.0 million by 2030, demonstrating a compound annual growth rate (CAGR) of 17.6% from 2025 to 2030. North America held the largest share of the global CyberKnife market, accounting for 41.5% of the revenue in 2024. Specifically, the U.S. CyberKnife market generated USD 259.8 million in revenue in 2024 and is expected to grow to USD 699.6 million by 2030, with a CAGR of 16.8% from 2025 to 2030.
TomoTherapy System (including Radixact System)
The global market for Helical Tomotherapy Systems, which includes Accuray's TomoTherapy and Radixact Systems, was valued at approximately USD 175 million in 2025. This market is forecast to reach USD 422 million by 2032, exhibiting a CAGR of 13.6% during the period of 2026-2032. Another estimate for the global Helical Tomotherapy market projects it to reach USD 367 million by 2031, growing at a CAGR of 13.3% from 2025 to 2031.
AI Analysis | Feedback
- Geographic Expansion, particularly in China and the broader Asia Pacific region: Accuray is prioritizing fast-growing emerging markets like China, India, and other parts of the Asia Pacific, where linear accelerator density remains below global benchmarks. A significant driver is the company's joint venture in China, which has begun manufacturing and selling systems like the Tomo C, following NMPA approval for its Radixact SynC and CyberKnife S7 Systems in January 2025. This expansion aims to capture multi-year capacity growth through provincial tenders associated with initiatives like "Healthy China 2030."
- Product Innovation and Upgrades: The company is focused on enhancing its product portfolio through the launch of new offerings and upgrades to existing platforms. This includes the introduction of new products, such as the Stellar product launched at ASTRO, which emphasizes adaptive radiotherapy and precision care. Accuray also aims to drive higher average selling prices (ASPs) by focusing on upgrades to its Radixact systems, including features like kV imaging, ClearRT, and Synchrony, as well as replacements for its CyberKnife S7 systems. These innovations are geared towards improving treatment accuracy, throughput, and aligning with demand for AI-enabled workflows and hypofractionation.
- Expansion of High-Margin Service Revenue: Accuray is committed to increasing its recurring service revenue by diversifying its offerings and expanding its global installed base. The company's strategy includes implementing higher pricing and reducing the cost of service, shifting towards a comprehensive solutions-oriented approach to enhance customer uptime and system performance. This focus on service portfolio expansion is expected to generate a more stable and predictable income stream, with service revenue already showing year-over-year growth.
AI Analysis | Feedback
Accuray (ARAY) has made several capital allocation decisions over the last three to five years, primarily focusing on managing its capital structure through share issuances and investments, while also undertaking capital expenditures for its operations.
Share Repurchases
- Accuray has not had any significant share repurchases or authorized buyback programs in the last 3-5 years.
Share Issuance
- In June 2025, Accuray completed an exchange of approximately $82.0 million in convertible senior notes due 2026 for 8,881,579 shares of common stock, alongside an approximate cash payment of $68.6 million.
- As of June 30, 2025, approximately 4.82 million shares were available for issuance under the company's 2016 Equity Incentive Plan.
- In February 2026, Accuray announced plans for a registered offering of up to 7 million shares of its common stock by selling stockholders.
- In December 2025, Accuray issued unregistered warrants for common shares to induce lenders, with exercise prices ranging from $0.01 to $1.50 per share, expiring in December 2032.
Inbound Investments
- In September 2025, Vanguard Group Inc. acquired 106,087 shares of Accuray Inc. at $1.67 per share, increasing its total holdings to 5,476,677 shares, reflecting a strategic interest in the medical devices sector.
Outbound Investments
- No significant outbound strategic investments or acquisitions by Accuray have been reported within the last 3-5 years.
Capital Expenditures
- Capital expenditures for the second quarter of fiscal year 2026 (ended December 31, 2025) totaled approximately -$1.904 million.
- Accuray's management notes that hospital capital expenditure globally remains robust, indicating a favorable environment for equipment purchases or leases.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 62.77 |
| Mkt Cap | 84.8 |
| Rev LTM | 15,599 |
| Op Inc LTM | 3,664 |
| FCF LTM | 3,066 |
| FCF 3Y Avg | 2,125 |
| CFO LTM | 3,851 |
| CFO 3Y Avg | 3,072 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.8% |
| Rev Chg 3Y Avg | 10.1% |
| Rev Chg Q | 9.9% |
| QoQ Delta Rev Chg LTM | 2.5% |
| Op Inc Chg LTM | 8.3% |
| Op Inc Chg 3Y Avg | 10.4% |
| Op Mgn LTM | 19.9% |
| Op Mgn 3Y Avg | 18.5% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 21.1% |
| CFO/Rev 3Y Avg | 19.9% |
| FCF/Rev LTM | 16.0% |
| FCF/Rev 3Y Avg | 15.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 84.8 |
| P/S | 3.1 |
| P/Op Inc | 15.5 |
| P/EBIT | 15.5 |
| P/E | 20.0 |
| P/CFO | 14.6 |
| Total Yield | 3.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.9% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -1.8% |
| 3M Rtn | -24.9% |
| 6M Rtn | -24.3% |
| 12M Rtn | -31.5% |
| 3Y Rtn | -8.3% |
| 1M Excs Rtn | -1.9% |
| 3M Excs Rtn | -32.6% |
| 6M Excs Rtn | -32.2% |
| 12M Excs Rtn | -50.0% |
| 3Y Excs Rtn | -76.5% |
Comparison Analyses
Price Behavior
| Market Price | $0.25 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 02/08/2007 | |
| Distance from 52W High | -86.5% | |
| 50 Days | 200 Days | |
| DMA Price | $0.34 | $0.72 |
| DMA Trend | down | down |
| Distance from DMA | -25.4% | -65.3% |
| 3M | 1YR | |
| Volatility | 144.3% | 99.8% |
| Downside Capture | 626.86 | 457.58 |
| Upside Capture | 241.27 | 166.25 |
| Correlation (SPY) | 28.8% | 31.2% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.72 | 2.94 | 3.23 | 2.66 | 2.54 | 1.82 |
| Up Beta | -1.73 | 2.78 | 2.32 | 2.81 | 2.47 | 1.50 |
| Down Beta | -1.15 | -1.25 | -0.56 | -0.08 | 1.16 | 1.45 |
| Up Capture | -7% | 229% | 380% | 262% | 243% | 319% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 10 | 19 | 31 | 58 | 105 | 316 |
| Down Capture | 343% | 520% | 514% | 277% | 200% | 113% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 11 | 22 | 32 | 67 | 133 | 377 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ARAY | |
|---|---|---|---|---|
| ARAY | -81.4% | 99.6% | -1.20 | - |
| Sector ETF (XLV) | 23.2% | 15.8% | 1.13 | 6.5% |
| Equity (SPY) | 20.3% | 12.6% | 1.19 | 31.4% |
| Gold (GLD) | 21.6% | 28.1% | 0.69 | 9.6% |
| Commodities (DBC) | 31.4% | 19.1% | 1.30 | -0.7% |
| Real Estate (VNQ) | 15.0% | 14.0% | 0.76 | 12.7% |
| Bitcoin (BTCUSD) | -44.6% | 42.9% | -1.25 | 17.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ARAY | |
|---|---|---|---|---|
| ARAY | -42.9% | 74.4% | -0.43 | - |
| Sector ETF (XLV) | 6.1% | 15.0% | 0.22 | 23.5% |
| Equity (SPY) | 12.9% | 17.1% | 0.58 | 35.8% |
| Gold (GLD) | 17.3% | 18.4% | 0.76 | 7.5% |
| Commodities (DBC) | 8.9% | 19.5% | 0.35 | 4.3% |
| Real Estate (VNQ) | 2.9% | 18.9% | 0.05 | 27.9% |
| Bitcoin (BTCUSD) | 14.9% | 53.4% | 0.46 | 16.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ARAY | |
|---|---|---|---|---|
| ARAY | -26.1% | 67.2% | -0.16 | - |
| Sector ETF (XLV) | 9.9% | 16.6% | 0.48 | 25.2% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 34.2% |
| Gold (GLD) | 11.2% | 16.1% | 0.57 | 5.1% |
| Commodities (DBC) | 7.2% | 17.9% | 0.32 | 10.2% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.21 | 26.7% |
| Bitcoin (BTCUSD) | 58.7% | 66.2% | 0.99 | 14.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/9/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/6/2026 | -38.6% | -36.7% | -28.3% |
| 2/4/2026 | -20.7% | -32.3% | -35.2% |
| 11/5/2025 | -15.9% | -18.6% | -31.8% |
| 8/13/2025 | -2.0% | 1.3% | 5.4% |
| 4/30/2025 | -12.9% | -12.3% | -1.3% |
| 2/5/2025 | 8.0% | -10.4% | -25.3% |
| 11/6/2024 | 3.0% | -10.8% | -1.0% |
| 8/14/2024 | 51.7% | 74.1% | 53.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 9 | 8 |
| # Negative | 14 | 15 | 16 |
| Median Positive | 7.3% | 13.6% | 16.0% |
| Median Negative | -10.2% | -13.5% | -17.3% |
| Max Positive | 51.7% | 74.1% | 59.9% |
| Max Negative | -38.6% | -36.7% | -35.2% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/6/2026 | -38.6% | -36.7% | -28.3% |
| 2/4/2026 | -20.7% | -32.3% | -35.2% |
| 11/5/2025 | -15.9% | -18.6% | -31.8% |
| 8/13/2025 | -2.0% | 1.3% | 5.4% |
| 4/30/2025 | -12.9% | -12.3% | -1.3% |
| 2/5/2025 | 8.0% | -10.4% | -25.3% |
| 11/6/2024 | 3.0% | -10.8% | -1.0% |
| 8/14/2024 | 51.7% | 74.1% | 53.1% |
| 5/1/2024 | -29.0% | -23.0% | -18.4% |
| 1/31/2024 | -1.2% | -4.6% | 0.8% |
| 11/7/2023 | -2.6% | -1.8% | -2.9% |
| 8/9/2023 | -12.5% | -19.2% | -26.9% |
| 4/26/2023 | 17.4% | 31.5% | 32.6% |
| 2/1/2023 | 17.6% | 27.3% | 22.9% |
| 11/2/2022 | 5.2% | 7.3% | 6.2% |
| 8/10/2022 | 21.1% | 33.9% | 9.2% |
| 4/27/2022 | -6.3% | -15.2% | -31.1% |
| 1/26/2022 | -15.2% | -9.1% | -12.5% |
| 11/3/2021 | 6.5% | 5.6% | -12.0% |
| 8/11/2021 | -2.3% | -11.1% | -7.8% |
| 4/27/2021 | -7.9% | -14.8% | -19.9% |
| 1/27/2021 | 3.3% | 2.0% | -4.0% |
| 10/29/2020 | 4.3% | 13.6% | 59.9% |
| 8/13/2020 | -5.7% | -13.5% | -16.1% |
| SUMMARY STATS | |||
| # Positive | 10 | 9 | 8 |
| # Negative | 14 | 15 | 16 |
| Median Positive | 7.3% | 13.6% | 16.0% |
| Median Negative | -10.2% | -13.5% | -17.3% |
| Max Positive | 51.7% | 74.1% | 59.9% |
| Max Negative | -38.6% | -36.7% | -35.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/17/2026 | 10-Q |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/28/2025 | 10-K |
| 03/31/2025 | 05/02/2025 | 10-Q |
| 12/31/2024 | 02/05/2025 | 10-Q |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 09/19/2024 | 10-K |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/07/2024 | 10-Q |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 09/07/2023 | 10-K |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 02/02/2023 | 10-Q |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/17/2022 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/17/2026 | 10-Q |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/28/2025 | 10-K |
| 03/31/2025 | 05/02/2025 | 10-Q |
| 12/31/2024 | 02/05/2025 | 10-Q |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 09/19/2024 | 10-K |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/07/2024 | 10-Q |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 09/07/2023 | 10-K |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 02/02/2023 | 10-Q |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/17/2022 | 10-K |
| 03/31/2022 | 04/29/2022 | 10-Q |
| 12/31/2021 | 01/28/2022 | 10-Q |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/17/2021 | 10-K |
| 03/31/2021 | 04/30/2021 | 10-Q |
| 12/31/2020 | 02/01/2021 | 10-Q |
| 09/30/2020 | 11/04/2020 | 10-Q |
| 06/30/2020 | 08/25/2020 | 10-K |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 02/04/2020 | 10-Q |
| 09/30/2019 | 11/06/2019 | 10-Q |
| 06/30/2019 | 08/23/2019 | 10-K |
Insider Activity
Updated 5/29/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Mayer, Steven F | Direct | Buy | 2232026 | 0.56 | 54,875 | 30,878 | 869,720 | Form | |
| 2 | Mayer, Steven F | Direct | Buy | 2202026 | 0.53 | 69,000 | 36,598 | 790,691 | Form | |
| 3 | Mayer, Steven F | Direct | Buy | 2202026 | 0.53 | 126,125 | 67,199 | 757,506 | Form | |
| 4 | La, Neve Stephen R | CEO | Direct | Buy | 11192025 | 0.97 | 20,000 | 19,410 | 19,410 | Form |
| 5 | Whitters, Joseph E | Direct | Buy | 6162025 | 1.25 | 50,000 | 62,335 | 761,800 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Mayer, Steven F | Direct | Buy | 2232026 | 0.56 | 54,875 | 30,878 | 869,720 | Form | |
| 2 | Mayer, Steven F | Direct | Buy | 2202026 | 0.53 | 69,000 | 36,598 | 790,691 | Form | |
| 3 | Mayer, Steven F | Direct | Buy | 2202026 | 0.53 | 126,125 | 67,199 | 757,506 | Form | |
| 4 | La, Neve Stephen R | CEO | Direct | Buy | 11192025 | 0.97 | 20,000 | 19,410 | 19,410 | Form |
| 5 | Whitters, Joseph E | Direct | Buy | 6162025 | 1.25 | 50,000 | 62,335 | 761,800 | Form |
Accuray — Investor Video Playlist
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.